NASDAQ$LMAT

LeMaitre Vascular Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

LeMaitre Vascular reported strong Q4 2024 financial results with significant growth in sales, operating income, and EPS.

LeMaitre Vascular reported a productive Q4 2024 with sales up 14%, operating income up 26%, and EPS up 30%. The company also announced an increased quarterly dividend and authorized a share repurchase program.

  • Sales increased 14% to $55.7 million in Q4 2024, driven by strong organic growth.
  • Operating income grew 26% to $12.9 million, with an operating margin of 23%.
  • Diluted earnings per share rose 30% to $0.49.
  • The company's cash balance increased sequentially to $299.7 million, providing strategic optionality.

Headline financials

Total Revenue

$55.7M

Previous: $48.9M+14.0%
EPS (adj)

$0.49

Previous: $0.38+28.9%
Gross Margin

69.3%

Previous: 68.1%+1.8%
Adjusted EBITDA

$15M

Previous: $12.8M+17.8%
Capital Expenditures

-$2.04M

No prior period
Net Income

$11.2M

Previous: $8.5M+31.6%
Operating Income

$12.9M

Previous: $10.2M+26.0%
Gross Profit

$38.6M

Previous: $33.3M+16.0%
R&D Expense

$3.62M

Previous: $4.35M-16.8%

Revenue & EPS history

LeMaitre Vascular · Revenue · Quarterly

$55.7M

Q4 2024+14%vs Q4 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Forward guidance

LeMaitre Vascular provided Q1 2025 and Full Year 2025 guidance, projecting continued growth in sales, operating income, and EPS.

Tailwinds

  • Q1 2025 sales guidance of $56.7mm - $58.7mm, representing 8%-10% organic growth.
  • Full Year 2025 sales guidance of $235.4mm - $242.8mm, representing 9%-10% organic growth.
  • Projected Q1 2025 operating income of $12.3mm - $13.7mm, with a 23% operating margin.
  • Projected Full Year 2025 operating income of $57.3mm - $62.4mm, with a 25% operating margin.
  • Projected Q1 2025 EPS of $0.48 - $0.53, representing 15% growth.

Headwinds

  • No specific negative guidance points were highlighted in the provided text.
  • Potential impact of currency exchange rate fluctuations on adjusted net sales.
  • Competition from other medical device companies and alternative medical technologies.
  • Ability to source, acquire, and integrate acquisitions.
  • Dependence on sole- or limited-source suppliers.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+1.2%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+1.5%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+24.3%

Q1 2017

Best reaction

-22.1%

Q3 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.6%-9.3%-15.7%
Q4 2025+24.2%+18.0%+16.7%
Q3 2025+1.4%+5.1%-1.2%
Q1 2025-13.0%-9.6%-8.9%
Q4 2024-8.1%-12.9%-16.9%
Q3 2024+6.5%+10.8%+20.1%
Q2 2024-2.2%-5.8%+3.9%
Q1 2024+11.1%+13.7%+18.1%
Q4 2023+15.2%+9.5%+7.6%
Q3 2023-4.0%+1.3%+10.8%
Q2 2023+2.3%-10.1%-8.6%
Q1 2023+15.4%+23.6%+17.1%
Q4 2022+6.2%+3.7%+5.2%
Q3 2022-19.6%-17.4%-11.5%
Q2 2022+4.7%+7.1%+3.8%
Q1 2022-2.9%-0.2%+2.6%
Q4 2021+6.2%+9.1%+3.0%
Q3 2021-5.2%-3.9%-11.2%
Q2 2021-0.5%+2.3%+2.9%
Q1 2021-2.8%-4.9%-5.1%
Q4 2020+7.8%+7.8%-2.0%
Q3 2020-1.7%+5.6%+19.8%
Q2 2020+13.3%+4.4%+3.9%
Q1 2020-14.1%-14.9%-12.4%
Q4 2019-20.1%-20.0%-23.6%
Q3 2019-1.5%+0.8%+1.8%
Q2 2019+0.8%+1.0%-4.4%
Q1 2019-8.2%-4.1%-10.6%
Q4 2018+22.3%+18.0%+24.3%
Q3 2018-22.1%-27.3%-25.8%
Q2 2018-7.1%-3.6%-4.5%
Q1 2018-16.6%-18.9%-16.2%
Q4 2017+1.6%+0.4%+0.9%
Q3 2017-17.7%-15.7%-8.2%
Q2 2017+17.4%+19.2%+17.9%
Q1 2017+24.3%+18.5%+17.9%
Q4 2016-6.9%-6.8%+1.3%
Q3 2016+9.4%+8.6%+24.9%
Q2 2016+15.1%+24.1%+21.4%
Q1 2016-1.4%
Q4 2015+18.5%
Q3 2015+11.0%
Q2 2015+14.0%
Q1 2015+0.0%
Q4 2014+2.2%
Q3 2014+3.0%
Q2 2014+3.5%
Q1 2014+4.6%
Q4 2013-2.2%
Q3 2013-1.4%
Q2 2013+1.2%
Q1 2013+1.5%
Q4 2012+3.3%
Q3 2012-0.6%
Q2 2012+1.6%
Q1 2012+0.3%
Q4 2009-1.2%
Q4 2011-1.2%
Q3 2010-1.9%
Q3 2011-1.9%
Q4 2010+0.1%
Q2 2011+0.1%
Q2 2010+0.1%
Q1 2011-1.1%
Q1 2010-3.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro